Compound Detail
CHEMBL2108724
SEMAGLUTIDE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
No structure available
Basic Information
| ChEMBL ID | CHEMBL2108724 |
| Name | SEMAGLUTIDE |
| Phase | Approved |
| Structure Type | SEQ |
| Therapeutic | ✓ Yes |
0
Targets
0
Activities
0
Assay Types
14
PK Parameters
0
Publications
12
Known Names
20
Indications
1
Mechanisms
Drug Information
| Molecule Type | Protein |
| First Approval | 2017 |
| Availability | Prescription |
| Chirality | Single Enantiomer |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Glucagon-like peptide 1 receptor agonist | AGONIST | Glucagon-like peptide 1 receptor | ✓ | ✓ |
Indications
Diabetes Mellitus Diabetes Mellitus, Type 2 Obesity Overweight Alzheimer Disease Cardiovascular Diseases Coronary Disease Diabetes Mellitus, Type 1 Klinefelter Syndrome Non-alcoholic Fatty Liver Disease Non-alcoholic Fatty Liver Disease Nutrition Disorders Pseudotumor Cerebri Alcoholism Asthma Depressive Disorder, Major Diabetic Nephropathies Ischemic Stroke Liver Diseases Parkinson Disease
ATC Classification
A10BJ06
semaglutide
Level 1: ALIMENTARY TRACT AND METABOLISM
Level 2: DRUGS USED IN DIABETES
Drug Warnings
Black Box Warning
carcinogenicity
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| CL | 0.02667 | mL.min-1.kg-1 | Sus scrofa |
| F | 94.0 | % | Sus scrofa |
| Ka | 9.24 | 10^4/Ms | Homo sapiens |
| Ka | 7.26 | 10^4/Ms | Homo sapiens |
| Ke | 1.33 | 10^-6M | Homo sapiens |
| MRT | 63.6 | hr | Sus scrofa |
| T1/2 | 160.0 | hr | Homo sapiens |
| T1/2 | 165.0 | hr | Homo sapiens |
| T1/2 | 46.1 | hr | Sus scrofa |
| T1/2 | 168.0 | hr | Homo sapiens |
| T1/2 | 48.0 | hr | Rattus norvegicus |
| T1/2 | 165.0 | hr | Homo sapiens |
| Tmax | 12.0 | hr | Sus scrofa |
| Vd | 0.1019 | L.kg-1 | Sus scrofa |
Data from ChEMBL 36 via Core Engine